The rapid EPS growth rate and the significant investment by company insiders indicate a strong confidence in the company's business strategy. These factors make WEX an attractive stock for growth investors to consider for further research.
More insider selling than buying at WEX in the last three months and over the longer term is somewhat bearish. Despite WEX's profitability and growth, low insider ownership and recent selling activity raise caution.
The high P/E ratio for WEX reflects investors' forecast of strong future growth, and their readiness to pay extra for the stock. Assuming steady earnings, this scenario may persist. Balance sheet risks and superior earnings outlook also play a part in the high P/E ratio.
Core Points Balanced risk-reward profile following impressive outperformance WEX has seen broad momentum across its business following a post-pandemic normalization period. The company has gained share in its core Mobility segment alongside impressive growth across Corporate Payments and Benefits aided by the recovery of travel volumes and float revenue on HSA balances. While we are optimistic on the long-term outloo...
WEX INCに関するコメント
コラムWEX(WEX US)| Share Gainer with Some Near-Term Headwinds Ahead; Initiate at Hold
Balanced risk-reward profile following impressive outperformance
WEX has seen broad momentum across its business following a post-pandemic normalization period. The company has gained share in its core Mobility segment alongside impressive growth across Corporate Payments and Benefits aided by the recovery of travel volumes and float revenue on HSA balances. While we are optimistic on the long-term outloo...
コラムBofA: 14 stocks likely to beat earnings estimates
コラムTop upgrades and downgrades on 4/5
• $クリーンハーバーズ(CLH.US)$ : Goldman Sachs Upgrades to Neutral from Sell - PT $120
• $イージーコープ(EZPW.US)$ : Jefferies Upgrades to Buy From Hold - PT $8.50
• $First Republic Bank(FRC.US)$ : Credit Suisse Upgrades to Neutral From Underperform - PT $187
• $ジェネラック・ホールディングス(GNRC.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $410
• $テバ・ファーマスーティカル・インダストリーズ(TEVA.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $13 (from $11)
• $ザイレム(XYL.US)$ ...
まだコメントはありません